Studies have shown that B cells expressing high levels of PD‐1 can contribute to a pro‐tumorigenic and chemo‐resistant phenotype in various types of tumors, including HCC.[25, 26] In contrast, tumor‐infiltrating B cells (TIL‐Bs) play a powerful anti‐tumor role, particularly in mature TLS, where they function as tumor‐specific antibody producers and antigen presenters.[27] This hinted that B cells within the tumor microenvironment can have multifaceted interactions with immunotherapy. The gene discussed is PDCD1; the disease is neoplasm.